OR WAIT null SECS
April 02, 2026
Article
Check out exclusive expert interviews of late breaking data from AAD 2026.
March 28, 2026
Video
Rosmarin discussed new late-breaking data from ADVANCE-AA at AAD 2026.
January 09, 2026
In this analysis, the 12-month use of a home-use helmet-type LLLT device was evaluated among individuals with androgenetic alopecia (AGA).
January 05, 2026
Investigators observed disparities in race with persistent chemotherapy-induced alopecia among women with breast cancer.
December 23, 2025
A review found increased anxiety, depression, social anxiety, and perceived stress among individuals with androgenetic alopecia compared with those without the condition.
To stay informed, catch up on some of the most notable alopecia areata news headlines from 2025 with our Year in Review.
December 18, 2025
Cosmo Pharmaceuticals released pivotal phase 3 findings on clascoterone treatment, a potential first-in-class medication designed to target androgenetic alopecia.
December 17, 2025
Topline findings from the phase 2b REZOLVE-AA trial highlight the efficacy of rezpegaldesleukin in severe-to-very-severe alopecia areata.
November 20, 2025
In this analysis, investigators examined the efficacy of baricitinib in terms of its impact on disease activity and progression of frontal fibrosing alopecia.
October 24, 2025
Once-daily oral baricitinib was shown to result in meaningful hair regrowth after 1 year in adolescent patients with alopecia areata.
